Chronic kidney disease affects approximately 850 million people globally and is a leading cause of cardiovascular morbidity and end-stage renal disease. The advent of SGLT2 inhibitors has established a new standard of care for cardiorenal protection across multiple CKD aetiologies. Novel agents targeting mineralocorticoid receptors, inflammation, and fibrosis pathways represent the next frontier in slowing disease progression.
Loading articles...
